Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 12/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060667 | 0.84 | CCR1 (0.66) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL5060058 | 0.76 | CCR1 (0.66) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6248231 | 0.75 | CCR1 (0.60) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6248232 | 0.75 | CCR1 (0.60) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL4633988 | 0.74 | RECQL (0.41) | PTGDR2ALDH1A1 | |
| SCHEMBL5059254 | 0.73 | CCR1 (0.69) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6255845 | 0.73 | CCR1 (0.59) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6077520 | 0.73 | CCR1 (0.62) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6076724 | 0.73 | CCR1 (0.58) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL5056171 | 0.73 | CCR1 (0.64) | CCR1PTGDR2FPR3GPR65GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | claimed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | CCR1 4304/4885PTGDR2 72/4885FPR3 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.